Current understanding of chemokine involvement in allograft transplantation

Pediatric Transplantation

Volumn 3, Issue 1, 1999, Pages 10-21

  Melter, M ^a   McMahon, G ^a   Fang, J ^b   Ganz, P ^b   Briscoe, David ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chemokines; Leucocyte recruitment; Transplantation

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

ALLOTRANSPLANTATION; ARTERIOSCLEROSIS; DIAGNOSTIC VALUE; DISEASE MARKER; GRAFT FAILURE; GRAFT REJECTION; PATHOGENESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCLEROSING CHOLANGITIS;

ANIMALS; CHEMOKINES; DISEASE MODELS, ANIMAL; GRAFT REJECTION; HUMANS; INFLAMMATION; RECEPTORS, CHEMOKINE; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032959410     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.1999.00023.x     Document Type: Review

References (113)

1. CECKA JM. The UNOS Scientific renal transplant registry - ten years of kidney transplants. In: CECKA JM, TERASAKI PI, eds. Clinical Transplants 1997. Los Angeles, California: UCLA Tissue Typing Laboratory, 1998. pp. 1-14.
2. TEJANI AH, SULLIVAN EK, HARMON WE, et al. Pediatric renal transplantation - the NAPRTCS experience. In: CECKA JM, TERASAKI PI, eds. Clinical Transplants 1997. Los Angeles, California: UCLA Tissue Typing Laboratory, 1998. pp. 87-100.
3. CHANDRAKER A, AZUMA H, NADEAU K, et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998: 101: 2309-2318.
4. RUSSELL ME, HANCOCK WW, AKALIN E, et al. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 1996: 97: 833-838.
5. ISHIBASHI M, AZUMA H, MARGONARI J, et al. Prevention of chronic rejection and puromycin-induced glomerulosclerosis in rats by gamma-lactone, an inhibitor of macrophage-effector activation. Transplant Proc 1996: 28: 953-954.
6. RUSSELL ME, WALLACE AF, WYNER LR, NEWELL JB, KARNOVSKY MJ. Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arteriosclerosis. Circulation 1995: 92: 457-464.
7. FURUTANI Y, NOMURA H, NOTAKE M, et al. Cloning and sequencing of the cDNA for human monocytes chemotactic and activating factor (MCAF). Biochem Biophys Res Commun 1989: 159: 249.
8. MATSUSHIMA K, LARSEN CG, DUBOIS GC, OPPENHEIM JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989: 169: 1485.
9. MATSUSHIMA K, OPPENHEIM JJ. Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL 1 and TNF. Cytokine 1989: 1: 2-13.
10. SCHALL TJ, JONGSTRA J, BRADLEY J, et al. A human T cell-specific molecule is a member of a new gene family. J Immunol 1988: 141: 1018-1025.
11. BAGGIOLINI M, DEWALD B, MOSER B. Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv Immunol 1994: 55: 97-179.
12. ROTH SJ, CARR MW, SPRINGER TA. C-C chemokines, but not the C-X-C chemokines interleukin-8 and interferon-gamma inducible protein-10, stimulate transendothelial chemotaxis of T-lymphocytes. Eur J Immunol 1995: 25: 3482-3488.
13. WALZ A, PEVERI P, ASCHAUER H, BAGGIOLINI M. Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem Biophys Res Commun 1987: 149: 755-761.
14. YOSHIMURA T, MATSUSHIMA K, TANAKA E, et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 1987: 84: 9233-9237.
15. SCHROEDER JM, MROWIETZ U, MORITA E, CHRISTOPHERS E. Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin I activity. J Immunol 1987: 139: 3474.
16. LOETSCHER M, GERBER B, LOETSCHER P, et al. Chemokine receptor specific for IP-10 and Mig: structure, function and expression in activated T-lymphocytes. J Exp Med 1996: 184: 963-969.
17. KELNER GS, KENNEDY J, BACON KB, et al. Lympotactin: a cytokine that represents a new class of chemokine. Science 1994: 266: 1395-1399.
18. BAZAN JF, BACON KB, HARDIMAN G, et al. A new class of membrane bound chemokine with a CX3C motif. Nature 1997: 385: 640-644.
19. GILAT D, HERSHKOVIZ R, MEKORI YA, VLODAVSKY I, LIDER O. Regulation of adhesion of CD+ T lymphocytes to intact or heparinase-treated subendothelial extracellular matrix by diffusible or anchored RANTES and MIP-1 beta. J Immunol 1994: 153: 4899-4906.
20. WIEDERMANN CJ, KOWALD E, REINISCH N, et al. Monocyte haptotaxis induced by the RANTES chemokine. Curr Biol 1993: 3: 735-739.
21. SPRINGER TA. Traffic signals for lymphocyte recirculation and leucocyte emigration: the multistep paradigm. Cell 1994: 76: 301-314.
22. BAGGIOLINI M. Chemokines and leukocyte traffic. Nature 1998: 392: 565-568.
23. COOK DN. The role of MIP-1 alpha in inflammation and hematopoiesis. J Leukocyte Biol 1996: 59: 61-66.
24. VERFAILLIE CM. Chemokines as inhibitors of hematopoietic progenitors. J Lab Clin Med 1996: 127: 148-150.
25. BACON KB, PREMACK BA, GARDNER P, SCHALL TJ. Activation of dual T cell signaling pathways by the chemokine RANTES. Science 1995: 269: 1727-1730.
26. TAUB DD, LLOYD AR, CONLON K, et al. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 1993: 177: 1809-1814.
27. VADDI K, NEWTON RC. Regulation of monocyte integrin expression by beta-family chemokines. J Immunol 1994: 153: 4721-4732.
28. ALAM R, STAFFORD S, FORSYTHE P, et al. RANTES is a chemotactic and activating factor for human eosinophils. J Immunol 1993: 150: 3442-3448.
29. KUNA P, REDDIGARI SR, SCHALL TJ, et al. RANTES a monocyte and T lymphocyte chemotactic cytokine release histamine from human basophils. J Immunol 1992: 149: 636-642.
30. TANAKA Y, ADAMS DH, HUBSCHER S, et al. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1beta. Nature 1993: 361: 79.
31. TAUB DD, SAYERS TJ, CARTER CR, ORTALDO JR. Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J Immunol 1995: 155: 3877-3888.
32. KOCH AE, POLVERINI PJ, KUNKEL SL, et al. Interleukin-8 as a macrophage derived mediator of angiogenesis. Science 1992: 258: 1798-1801.
33. STRIETER RM, KUNKEL SL, ELNER VM, et al. Interleukin-8 a corneal factor that induces neovascularization. Am J Pathol 1992: 141: 1279-1284.
34. SMITH DR, POVERINI PJ, KUNKEL SL, et al. Inhibitition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 1994: 179: 1409.
35. ARENBERG DA, POLVERINI PJ, KUNKEL SL, et al. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukocyte Biol 1997: 62: 554-562.
36. ANGIOLILLO AL, SGADARI C, TOSATO G. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann NY Acad Sci 1996: 795: 158-167.
37. WU D, LAROSA GJ, SIMON MI. G protein-coupled signal transduction pathways for interleukin-8. Science 1993: 261: 101-103.
38. ARAI H, CHARO IF. Differential regulation of G-protein-mediated signaling by chemokine receptors. J Biol Chem 1996: 271: 21814-21819.
39. KUANG Y, WU Y, JIANG H, WU D. Selective G protein coupling by C-C chemokine receptors. J Biol Chem 1996: 271: 3975-3978.
40. GUDERMANN T, KALKBRENNER F, SCHULTZ G. Diversity and selectivity of receptor-G protein interaction. Annu Rev Pharmacol Toxicol 1996: 36: 429-459.
41. ROLLINS BJ. Chemokines. Blood 1997: 90: 909-928.
42. SOTO H, WANG W, STRIETER RM, et al. The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. Proc Natl Acad Sci USA 1998: 95: 8205-8210.
43. CAMPBELL JJ, FOXMAN EF, BUTCHER EC. Chemoattractant receptor cross talk as a regulatory mechanism in leukocyte adhesion and migration. Eur J Immunol 1997: 27: 2571-2578.
44. TANAKA H, SUKHOVA GK, LIBBY P. Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts. Arteriosclerosis Thrombosis 1994: 14: 734-745.
45. BRISCOE DM, GANZ P, ALEXANDER SI, et al. The problem of chronic rejection: Influence of leukocyte-endothelial interactions. Kidney Int 1997: 51: 22-27.
46. DEVERGNE O, MARFAING-KOKA A, SCHALL TJ, et al. Production of the RANTES chemokine in delayed-type hypersensitivity reactions: involvement of macrophages and endothelial cells. J Exp Med 1994: 179: 1689-1694.
47. MONTI G, MAGNAN A, FATTAL M, et al. Intrapulmonary production of RANTES during rejection and CMV pneumonitis after lung transplantation. Transplantation 1996: 61: 1757-1762.
48. LIM KG, WAN HC, BOZZA PT, et al. Human eosinophils elaborate the lymphocyte chemoattractants. IL-16 (lymphocyte chemoattractant factor) and RANTES. J Immunol 1996: 156: 2566-2570.
49. SCHALL TJ, BACON K, TOY KJ, GOEDDEL DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990: 347: 669-671.
50. MAGHAZACHI AA, AL-AOUKATY A, SCHALL TJ. CC chemokines induce the generation of killer cells from CD56+ cells. Eur J Immunol 1996: 26: 315-319.
51. ROT A, KRIEGER M, BRUNNER T, BISCHOFF SC, SCHALL TJ, DAHINDEN CA. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med 1992: 176: 1489-1495.
52. UGUCCIONI M, D'APUZZO M, LOETSCHER M, DEWALD B, BAGGIOLINI M. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes. Eur J Immunol 1995: 25: 64-68.
53. NAGANO H, NADEAU KC, TAKADA M, KUSAKA M, TILNEY NL. Sequential cellular and molecular kinetics in acutely rejecting renal allografts in rats. Transplantation 1997: 63: 1101-1108.
54. NATHAN MJ, LI K, PICCOTTI JR, et al. Chemokine regulation of T cell entry into vascularized allografts: a central role for lymphotactin? Transplantation 1998: 65: S33.
55. KONDO T, NOVICK AC, TOMA H, FAIRCHILD RL. Induction of chemokine gene expression during allogeneic skin graft rejection. Transplantation 1996: 61: 1750-1757.
56. NADEAU KC, AZUMA H, TILNEY NL. Sequential cytokine dynamics in chronic rejection of rat renal allografts: roles for cytokines RANTES and MCP-1. Proc Natl Acad Sci USA 1995: 92: 8729-8733.
57. FAIRCHILD RL, VANBUSKIRK AM, KONDO T, WAKELY ME, OROSZ CG. Expression of chemokine genes during rejection and long-term acceptance of cardiac allografts. Trans-plantation 1997: 63: 1807-1812.
58. MAGNAN A, MEGE JL, REYNAUD M, et al. Monitoring of alveolar macrophage production of tumor necrosis factor-alpha and interleukin-6 in lung transplant recipients. Am J Respir Crit Care Med 1994: 150: 684.
59. HUMBERT M, CERRINA J, RAIN B, et al. Interleukin 1 beta, interleukin-6, and serine esterase B gene expression in bronchio-alveolar cells after lung and heart-lung transplantation. Am Rev Respir Dis 1991: 143: A600.
60. SMITH PD, SAINI SS, RAFFELD M, MANISCHEWITZ JF, WAHL SM. Cytomegalovirus induction of tumor necrosis factor-alpha by human monocytes and mucosal macrophages. J Clin Invest 1992: 90: 1642.
61. RATHANASWAMI P, HACHICHA M, SADICK M, SCHALL TJ, McCOLL SR. Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J Biol Chem 1993: 268: 5834-5839.
62. PATTISON J, NELSON PJ, HUIE P, et al. RANTES chemokine expression in cell-mediated transplant rejection of the kidney. Lancet 1994: 343: 209-211.
63. PATTISON JM, NELSON PJ, HUIE P, SIBLEY RK, KRENSKY AM. RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J Heart Lung Transplant 1996: 15: 1194-1199.
64. WOLPE SD, DAVATELIS G, SHERRY B, et al. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med 1988: 167: 570-581.
65. SHERRY B, TEKAMP-OLSON P, GALLEGOS C, et al. Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein 1 beta. J Exp Med 1988: 168: 2251-2259.
66. FAHEY TJ, 3, TRACEY KJ, TEKAMP-OLSON P, et al. Macrophage inflammatory protein 1 modulates macrophage function. J Immunol 1992: 148: 2764-2769.
67. TAUB DD, CONLON K, LLOYD AR, OPPENHEIM JJ, KELVIN DJ. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. Science 1993: 260: 355-357.
68. SCHALL TJ, BACON K, CAMP RDR, KASPARI JW, GOEDDEL DV. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med 1993: 177: 1821-1825.
69. SOZZANI S, SALLUSTO F, LUINI W, et al. Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J Immunol 1995: 155: 3292-3295.
70. LOETSCHER P, SEITZ M, CLARK-LEWIS I, BAGGIOLINI M, MOSER B. Activation of NK cells by CC chemokines. Chemotaxis, Ca2+ mobilization, and enzyme release. J Immunol 1996: 156: 322-327.
71. DAHINDEN CA, GEISER T, BRUNNER T, et al. Monocyte chemotactic protein 3 is a most effective basophil-and eosinophil-activating chemokine. J Exp Med 1994: 179: 751-756.
72. ALAM R, KUMAR D, ANDERSON-WALTERS D, FORSYTHE PA. Macrophage inflammatory protein-1 alpha and monocyte chemoattractant peptide-1 elicit immediate and late cutaneous reactions and activate murine mast cells in vivo. J Immunol 1994: 152: 1298-1303.
73. ALAM R, FORSYTHE PA, STAFFORD S, LETT-BROWN MA, GRANT JA. Macrophage inflammatory protein-1 alpha activates basophils and mast cells. J Exp Med 1992: 176: 781-786.
74. GRAHAM GJ, WRIGHT EG, HEWICK R, et al. Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature 1990: 344: 442-444.
75. ADAMS DH, HUBSCHER S, FEAR J, JOHNSTON J, SHAW S, AFFORD S. Hepatic expression of macrophage inflammatory protein-1 alpha and macrophage inflammatory protein-1 beta after liver transplantation. Transplantation 1996: 61: 817-825.
76. LENTSCH AB, YOSHIDOME H, CHEADLE WG, et al. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: Roles for macrophage inflammatory protein-2 and KC. Hepatology 1998: 27: 507-512.
77. FAHEY TJ, SHERRY B, TRACEY KJ, et al. Cytokine production in a model of wound healing: the appearance of MIP-1, MIP-2, cachectin/TNF and IL-1. Cytokine 1990: 2: 92-99.
78. LUKACS NW, KUNKEL SL, BURDICK MD, STRIETER RM. The production of chemotactic cytokines in an allogeneic response. The role of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3. Am J Pathol 1993: 143: 1179.
79. LUKACS NW, KUNKEL SL, BURDICK MD, LINCOLN PM, STRIETER RM. Interleukin-1 receptor antagonist blocks chemokine production in the mixed lymphocyte reaction. Blood 1993: 82: 3668.
80. VALENTE AJ, GRAVES DT, VIALLE-VALENTIN CE, DELGADO R, SCHWARTZ CJ. Purification of a monocyte chemotactic factor secreted by nonhuman primate vascular cells in culture. Biochemistry 1988: 27: 4162-4168.
81. ROLLINS BJ, MORRISON ED, STILES CD. Cloning and expression of JE, a gene inducible by platelet-derived growth factor and whose product has cytokine-like properties. Proc Natl Acad Sci USA 1988: 85: 3738-3742.
82. JIANG Y, BELLER DI, FRENDL G, GRAVES DT. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 1992: 148: 2423-2428.
83. CARR MW, ROTH SJ, LUTHER E, ROSE SS, SPRINGER TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 1994: 91: 3652-3656.
84. ALLAVENA P, BIANCHI G, ZHOU D, et al. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol 1994: 24: 3233-3236.
85. LOETSCHER P, SEITZ M, CLARK-LEWIS I, BAGGIOLINI M, MOSER B. Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes. FASEB J 1994: 8: 1055-1060.
86. BISCHOFF SC, KRIEGER M, BRUNNER T, DAHINDEN CA. Monocyte chemotactic protein 1 is a potent activator of human basophils. J Exp Med 1992: 175: 1271-1275.
87. KUNA P, REDDIGARI SR, RUCINSKI D, OPPENHEIM JJ, KAPLAN AP. Monocyte chemotactic and activating factor is a potent histamine-releasing factor for human basophils. J Exp Med 1992: 175: 489-493.
88. ALAM R, LETT-BROWN MA, FORSYTHE PA, et al. Monocyte chemotactic and activating factor is a potent histamine-releasing factor for basophils. J Clin Invest 1992: 89: 723-728.
89. FAIRCHILD RL. Chemokines. Mediators of T cell recruitment and effector function during allograft rejection? Graft 1998: 1: 91-95.
90. CHRISTENSEN PJ, ROLFE MW, STANDIFORD TJ, et al. Characterization of the production of monocyte chemoattractant protein-1 and IL-8 in an allogenic immune response. J Immunol 1993: 151: 1205-1213.
91. RUSSELL ME, ADAMS DH, WYNER LR, YAMASHITA Y, HALNON NJ, KARNOVSKY MJ. Early and persistent induction of monocyte chemoattractant protein 1 in rat cardiac allografts. Proc Natl Acad Sci USA 1993: 90: 6086-15090.
92. GRANDALIANO G, GESUALDO L, RANIERI E, MONK R, STALLONE G, SCHENK FP. Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection. Transplantation 1997: 63: 414-420.
93. SOLEZ K, AXELSEN RA, BENEDIKTSSON H, et al. International standardization of criteria of the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993: 44: 411.
94. CROCKER BP, SALOMON DR. Pathology of the renal allograft. In: TISHER CC, BRENNER BM, eds. Renal Pathology. Philadelphia, PA: Lippincott, 1989. pp. 1518.
95. SCHMOUDER RL, STRIETER RM, WALZ A, KUNKEL SL. Epithelial-derived neutrophil-activating factor-78 production in human renal tubule epithelial cells and in renal allograft rejection. Transplantation 1995: 59: 118-124.
96. HEEMANN UW, TULLIUS SG, AZUMA A, et al. Infiltration patterns of macrophages and lymphocytes in chronically rejecting rat kidney allografts. Transplant Int 1994: 7: 349-355.
97. McDIARMID SV, FARMER DG, KUNIYOSHI JS, et al. The correlation of intragraft cytokine expression with rejection in rat small intestine transplantation. Transplantation 1994: 58: 690-697.
98. DALLMAN MJ. Cytokines as mediator of organ graft rejection and tolerance. Curr Opin Immunol 1993: 5: 788-793.
99. WILLIAMS TJ, HELLEWELL PG. Endothelial cell biology. Adhesion molecules involved in the macrovascular inflammatory response. Am Rev Respir Dis 1992: 146: 45-50.
100. STREHLAU J, PAVLAKIS M, LIPMAN M, et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 1997: 94: 695-700.
101. HANCOCK WW, SAYEGH MH, ZHENG XG, PEACH R, LINSLEY PS, TURKA LA. Costimulatory function and expression of CD40 ligand, CD80 and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci USA 1996: 93: 13967-13972.
102. LIPMAN ML, STEVENS AC, STROM TB. Cytotoxic T lymphocyte (CTL) and immunosuppressive cytokine gene expression in human renal allograft biopsies. J Am Soc Nephrol 1992: 3: 867.
103. WIEDER KJ, HANCOCK WW, SCHMIDBAUER G, et al. Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B, and IFN-gamma in rat recipients of cardiac allografts. J Immunol 1993: 151: 1158-1166.
104. SMITH RE, STRIETER RM, PHAN SH, et al. Production and function of murine macrophage inflammatory protein-1 alpha in bleomycin-induced lung injury. J Immunol 1994: 153: 4704.
105. LIN HS, CHENSUE W, STRIETER RM, et al. Antibodies against tumor necrosis factor prolong cardiac allograft survival in the rat. J Heart Lung Transplant 1992: 11: 330-335.
106. FANSLOW WC, SIMS JE, SASSENFELD H, et al. Regulation of allograft reactivity in vivo by a soluble form of the interleukin-1 receptor. Science 1990: 248: 739.
107. PIGUET PF, VESIN C, GRAU GE, THOMPSON RC. Interleukin-1 receptor antagonist (IL-1 ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 1993: 5: 57-61.
108. TOPHAM P, HINES D, CSIZMADIA V, GERARD C, SALANT DI, HANCOCK WW. Regulatory role of CCR1 pathway in glomerulonephritis (GN) CCR1 knockout mice show enhanced glomerular injury. J Am Soc Nephrol 1998: 9: 487A(abstract).
109. KONDO T, WATARAI Y, NOVICK AC, TOMA H, FAIRCHILD RL. T cell-dependent acceleration of chemoattractant cytokine gene expression during secondary rejection of allogeneic skin grafts. Transplantation 1997: 63: 732-742.
110. VAPNEK E, HOBART M, KONDO T, et al. Early intragraft expression of chemokine genes during acute rejection of allogeneic cardiac grafts. Transplantation 1998: 65: S32.
111. CZISMADIA V, SEVILLANO S, TURKA L, et al. Co-stimulation alters intragraft chemokine expression: rejection is linked to CXCR3+ cells and ligands IP-10 and MIG whereas long-term survival is associated with their suppression and infiltration by CCR2+ cells. Transplantation 1998: 65: S90.
112. EITNER F, CUI Y, HUDKINS KL, ALPERS CE. Chemokine Receptor (CXCR4) mRNA-expressing leukocytes are increased in human renal allograft rejection. J Am Soc Nephrol 1998: 9: 649A (Abstract).
113. RUSSELL ME, HANCOCK WW, WALLACE AF, WYNER LR, KARNOVSKY MJ. Modulation of inflammatory activation pathways in the Lewis-to-F-344 rat chronic cardiac rejection model. Transplant Proc 1995: 27: 2100-2104.